Viral vector manufacturing and platform evolution

CELL AND GENE THERAPY INSIGHTS

October 2025

Viral vector manufacturing and platform evolution

Expert Insight

Impurities in viral-based therapeutics: mastering residual hcDNA: a harmonized approach for AAV gene therapies

Impurities in viral-based therapeutics: mastering residual hcDNA: a harmonized approach for AAV gene therapies

R Sundar, X Mi, A Lavoie et al.

Review

Process and analytical development during AAV manufacturing platform evolution

Process and analytical development during AAV manufacturing platform evolution

Jack Jinqi Ren, Ning Ding

Innovator Insight

Regulatory path transitioning from transient to stable cell lines for AAV manufacturing

Regulatory path transitioning from transient to stable cell lines for AAV manufacturing

E Cameau, E Nguyen, A Pedregal et al.

How far have AAV platforms taken us? Lessons from a CDMO on accelerating time-to-clinic

How far have AAV platforms taken us? Lessons from a CDMO on accelerating time-to-clinic

A simplified chromatography method for robust separation of full and empty AAV capsids: a case study with AAV2

A simplified chromatography method for robust separation of full and empty AAV capsids: a case study with AAV2

D Catalán-Tatjer, C Toussaint, B Paes et al.

Interview

Unpacking the challenges of AAV gene therapy: exploring capsid engineering, immunogenicity management, and scalable manufacturing solutions

Unpacking the challenges of AAV gene therapy: exploring capsid engineering, immunogenicity management, and scalable manufacturing solutions

Webinars

Exploring key regulatory considerations to ensure patient safety in the gene therapy space

Exploring key regulatory considerations to ensure patient safety in the gene therapy space

L Shaw, C Le Bec, M Orio et al.

Next-gen vectors: advancing in vivo and ex vivo gene delivery through intelligent design

Next-gen vectors: advancing in vivo and ex vivo gene delivery through intelligent design

N Habib, J Maher, C Scala

Ensuring success in AAV scale-up: key data from case studies across four serotypes

Ensuring success in AAV scale-up: key data from case studies across four serotypes

Kelly Cybulski, Kyle Burrell

Ensuring success in AAV scale-up: key data from case studies across four serotypes (APAC)

Ensuring success in AAV scale-up: key data from case studies across four serotypes (APAC)

K Cybulski, K Burrell, A Low (Joining for Q&A)

Viral vector manufacturing: optimization through culture, QC and regulatory standards

Viral vector manufacturing: optimization through culture, QC and regulatory standards

J Cody, M Sharma, G Gayosa

Achieving scalable, high-yield plasmid DNA purification processes

Achieving scalable, high-yield plasmid DNA purification processes

Klemen Božič

A science-driven framework for EV characterization to achieve clinical success

A science-driven framework for EV characterization to achieve clinical success

Davide Zocco

Optimizing upstream cell culture with rapid at-line and in-line analytics

Optimizing upstream cell culture with rapid at-line and in-line analytics

Nick Randall, Ethan Bossange

Accelerating AAV process development with high-throughput strategies

Accelerating AAV process development with high-throughput strategies

Dan Matuszek

Smarter lentiviral manufacturing for CAR-T: increased productivity meets smart purification

Smarter lentiviral manufacturing for CAR-T: increased productivity meets smart purification

Jean-Simon Diallo, Jason Slingby

Scaling AAV5 production from bench to industrial scale: strategies for efficient, de-risked manufacturing

Scaling AAV5 production from bench to industrial scale: strategies for efficient, de-risked manufacturing

Anne MacIntyre, Sara Krekels